“I am thrilled to be utilizing my cell therapy launch experience to support TScan in its mission to deliver life-changing TCR-T therapies to patients fighting a variety of heme and solid tumor malignancies.”
Stephen Camiolo is our Senior Vice President, Market Access. Stephen has over 25 years of experience in market access, reimbursement, pricing strategy, sales, marketing, and account management across the pharmaceutical and biotechnology industries. His experience includes over 16 successful product launches across multiple disease areas, three of which were cell therapies. Prior to joining TScan, Stephen was Vice President, National Cell Therapy Account Teams at Iovance Biotherapeutics, Inc., where he led his team in the strategic launch of the first cell therapy to treat solid tumor cancer, AMTAGVI®. Before joining Iovance, Stephen was Vice President, Market Access, Pricing, and Interim Head of Commercial at CRISPR Therapeutics AG, where he led the Company’s global market access, reimbursement, and pricing strategy functions for various allogeneic CAR-T programs. Stephen has also held sales and marketing roles of increasing responsibility at Gilead Sciences, Inc., and was appointed Executive Director, Market Access Strategy, Pricing, and National Accounts at Kite Pharma, Inc., following its acquisition by Gilead in 2017. Stephen began his career at Novartis Pharmaceuticals Corporation and holds a B.S.N. from Spalding University.
When not at TScan, Stephen enjoys flying, traveling, hiking, fishing, and spending quality time with his family.